Article citationsMore>>

F. Locatelli, M. Zecca, P. Pedrazzoli, L. Prete, S. Quaglini, P. Comoli, P. De Stefano, Y. Beguin, G. Robustelli della Cuna, F. Severi, “Use of Recombinant Human Erythropoietin after Bone Marrow Transplantation in Pediatric Patients with Acute Leukemia: Effect on Erythroid Repopulation in Autologous versus Allogeneic Transplants,” Bone Marrow Transplantation, Vol. 13, No. 4, 1994, pp. 403-410.

has been cited by the following article:

• TITLE: Darbepoietin-Alfa after High-Dose Melphalan and Autologous Hemopoietic Progenitor Cell in Multiple Myeloma Patients: A Pilot Study

  AUTHORS: Massimo Martino, Ida Callea, Tiziana Moscato, Antonella Pontari, Elisa Spiniello, Roberta Fedele

  KEYWORDS: Darbepoietin-Alfa; Anemia; Multiple Myeloma; Autologous Hematopoietic Progenitor Cell Transplanta-tion

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.2 No.3, September 4, 2012

  ABSTRACT: We describe the effects of Darbepoietin-alfa (Darbe) administration in Multiple Myeloma (MM) after autologous he-mopoietic progenitor cell transplantation (AHPCT). 26 MM patients undergoing AHPCT entered this study. 34 hemo-globin (Hb)-matched patients who had not received recombinant human erythropoietin (Epo) or Darbe and were treated with the same protocol were retrospectively selected for comparative data. Darbe (150 micro g total dose/weekly) was initiating in four weeks after AHPCT, with the aim of achieving an Hb level of ≥11 g/dl. The time to response to Darbe therapy was longer in the patients with Hb